Neurocrine Biosciences NBIX
NASDAQ NBIX
$141.84 +3.49 (+2.52%)
At close: Sep 30, 2026 · 4:00 PM EDT

Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024)

Updated

Neurocrine Biosciences' Debt Ratio came in at 0.04 for Q1 2024, down 32.4% from the prior quarter.

Analysis

Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024) Analysis & Trends

For FY2023, Neurocrine Biosciences' Debt Ratio was 0.05, down 26.8% from FY2022.

  • Going back by year, Debt Ratio was 0.07 in FY2022 and 0.31 in FY2019.
  • The Q1 2024 figure represents the lowest quarterly Debt Ratio in data going back to Q3 2018.
  • Business Quant data shows NBIX's Debt Ratio at 0.05 (Q4 2023), 0.06 (Q3 2023) and 0.06 (Q2 2023) in the three quarters before Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Neurocrine Biosciences 14.06 Bn 9.76 Bn 935.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 0.04
Dec 31, 2023 0.05
Sep 30, 2023 0.06
Jun 30, 2023 0.06
Dec 31, 2022 0.07
Sep 30, 2022 0.08
Sep 30, 2020 0.28
Jun 30, 2020 0.28
Dec 31, 2019 0.31
Sep 30, 2018 0.41
API Access

Neurocrine Biosciences Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=NBIX&period=max&api_key=YOUR_API_KEY